Aldeyra Misses Mark in Phase 3 Dry Eye Trial

 

• TRANQUILITY Primary Endpoint of Ocular Redness Not Met, but Statistical Significance Achieved for Secondary Endpoint of Schirmer Test (p=0.0001), an Approvable Sign of Dry Eye Disease

• Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022

• Dry Eye Disease NDA Submission Expected Mid-2022, Pending Safety Trial Enrollment and Outcome of TRANQUILITY-2

• Company to Host Conference Call at 5:00 p.m. ET Today

Conference Call Information

Aldeyra will host a conference call to discuss this announcement at 5:00 p.m. ET today, December 20, 2021. The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID is 8641858. A live webcast of the conference call will also be available on the "Investors & Media section" of the Aldeyra Therapeutics website at https://ir.aldeyra.com. Presentation slides will be available on the investor relations page prior to the start of the conference call and webcast.

https://finance.yahoo.com/news/aldeyra-therapeutics-announces-top-line-210500133.html